Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02918461
Other study ID # Pro00046105
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2017
Est. completion date November 2017

Study information

Verified date January 2019
Source Cedars-Sinai Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

At Cedars-Sinai Medical Center, the investigators have developed a novel curriculum for a 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2-2.5 hours for 6 weeks.

The objective of this study is to quantify the impact of a trainee-taught Emerging from the Haze course on gynecologic cancer survivors' self-report of cognitive changes based on the change of FACT-Cog score.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date November 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of any stage gynecologic cancer including ovarian, uterine/endometrial, cervical, vulvar, and vaginal cancer

- Treated with chemotherapy solely or in combination with surgery, radiation, and/or hormonal therapy

- Female, age = 18 years.

- FACT-Cog score < 59 on the PCI sub scale

- Eligible after 2 months (60 ±5 days) of completing all their active cancer treatment with the exception of long-term hormonal treatments

- Subjective complaint of cognitive concerns at time of enrollment

- Must be able to understand and communicate proficiently in English

- Ability to understand and the willingness to sign a written informed consent.

- Agree to complete study surveys

Exclusion Criteria:

- Patients who have significant personality disorders or unstable psychiatric disorders (including active major depression, substance abuse, psychosis or bipolar disorder) as assessed by the interviewing clinician

- Patients with known brain metastases, history of brain metastases or radiation to the brain.

- Patients with a history of stroke or other pre-existing neurological condition that may contribute to cognitive dysfunction.

- Non-English speakers

- Receiving treatment for another malignancy other than breast cancer

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, chronic anemia, uncontrolled hypothyroidism, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Study Design


Intervention

Behavioral:
Emerging from the Haze class
A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.

Locations

Country Name City State
United States Cedars Sinai Medical Center Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Cedars-Sinai Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Comparison of trainee-taught vs non-trainee taught class To compare the impact of a trainee-taught Emerging from the Haze course on gynecologic cancer survivors' self report of cognitive changes based on change of the FACT-Cog compared to the impact of an ongoing non-trainee-taught Emerging from the Haze course on breast cancer survivors' self report of cognitive changes based on the change in FACT-Cog score from first day of class (baseline) to last day of class (6 weeks) in these two groups First day of class (baseline), last day of class (6 weeks)
Primary The Functional Assessment of Cancer Therapy- Cognition (FACT-Cog) Survey Measure the change in score from baseline to each of three time points: last day of class (6 weeks), 6 months, and 1 year after class First day of class (baseline), last day of class (6 weeks), 6 months and 1 year after class
Secondary Patient Reported Outcomes Measurement Information System (PROMIS) - Cognition and General Concerns Survey Measure the change in score from baseline to each of three time points: last day of class (6 weeks), 6 months, and 1 year after class First day of class (baseline), last day of class (6 weeks), 6 months and 1 year after class
Secondary UCLA Loneliness Scale Survey Measure the change in score from baseline to each of three time points: last day of class (6 weeks), 6 months, and 1 year after class First day of class (baseline), last day of class (6 weeks), 6 months and 1 year after class
See also
  Status Clinical Trial Phase
Completed NCT02488720 - Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Recruiting NCT03544801 - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting NCT02813434 - Cerebral Amyloid Imaging Using Florbetapir (AV-45) Phase 3
Completed NCT00400790 - Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane N/A
Completed NCT00052091 - Therapy for Depressed Elders With Thought Problems Phase 3
Completed NCT00021866 - Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy N/A
Completed NCT00267163 - Brain Imaging and Mental Disorders of Aging Intervention Phase 4
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Terminated NCT03696082 - A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines N/A
Completed NCT02918539 - Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Active, not recruiting NCT01708837 - Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction Phase 4
Completed NCT01290939 - Bevacizumab and Lomustine for Recurrent GBM Phase 3
Terminated NCT00548327 - The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype Phase 2
Unknown status NCT00256425 - Cognitive Rehabilitation of Glioma Patients Phase 3
Recruiting NCT03926351 - High Dose Omega 3 in People at Risk for Dementia Phase 2
Completed NCT02118571 - Schizophrenia Cognition Scale Development N/A
Completed NCT01481961 - Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease N/A
Completed NCT00788918 - Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) N/A
Completed NCT00564902 - The Zeaxanthin and Visual Function Study N/A
Completed NCT00529581 - A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis Phase 2